Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer-Reference-Cited by-同舟云学术

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

Published:2013-07-09 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Lawrie Theresa A¹,Bryant Andrew²,Cameron Alison³,Gray Emma⁴,Morrison Jo⁵

Affiliation:

1. Royal United Hospital; Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group; Education Centre Bath UK BA1 3NG

2. Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX

3. University Hospitals Bristol NHS Foundation Trust; Department of Clinical Oncology; Bristol Haematology and Oncology Centre Horfield Road Bristol UK BS2 8ED

4. Musgrove Park Hospital; The Beacon Centre; Taunton Somerset UK TA1 5DA

5. Musgrove Park Hospital; Department of Gynaecological Oncology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006910.pub2/fullpdf

Reference152 articles.

1. Rose P Edwards R Finkler N Seiden M Duska L Krasner C Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC) Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 2007

2. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer;Vergote;International Journal of Gynecological Cancer,2010

3. Vergote I Phase 3 study of canfosfamide (TLK 286) plus pegylated liposomal doxorubicin (PLD) vs PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer Journal of Clinical Oncology; 2009 ASCO annual meeting 2009

4. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial;Alexandre;British Journal of Cancer,2012

5. Alexandre J Brown C Priou F De Rauglaudre G Pfisterer J Maenpaa J Should CA 125 still be part of tumour evaluation criteria in ovarian cancer trials? Experience of the GCIG calypso trial Annals of Oncology, 35th ESMO Congress, Milan, Italy 2010 viii 307: abstr. 981P

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer;Drug Delivery and Translational Research;2024-06-17

2. Relapsed Ovarian Cancer Patients with Ascites and/or Pleural Effusion Still Benefit from Treatment: A Real-Life Study;Cancers;2023-12-28

3. Molecular mechanisms of cisplatin resistance in ovarian cancer;Genes & Diseases;2023-08

4. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-07-05

5. Epithelial Ovarian Cancer: A Five Year Review;Medicina;2023-06-21